Here's where 17-year cicadas are the worst in Cincinnati, Southwest Ohio. See the map

They're causing chaos at King's Island. They're being blamed for car crashes.
Millions of not billions of 17-year cicadas in Brood XIV have emerged in Cincinnati and Southwest Ohio. And even though they've been around for weeks, they are still making themselves known: Screaming from plants and trees, making a mess and peeing on everything.
But their time is growing short. Gene Kritsky, professor emeritus of biology with Mount St. Joseph University in Cincinnati, said in a June 16 email that people in the areas heaviest with cicadas should start "to notice things getting quieter next week."
What areas are those? Here's where the largest number of cicadas have been in the Greater Cincinnati area, according to Kritsky.
Kritsky, founder of Cicada Safari, an app that crowdsources and reviews data on cicadas, was out mapping the 17-year cicada emergence as recently as Monday, June 16, said the heaviest presence of 17-year cicadas have been in Loveland and Mason, northeast of Cincinnati, as well as Pattison Park in Batavia and East Fork State Park in Bethel, both roughly 25 miles east of the Queen City.
According to the map generated by Cicada Safari, where users can submit reports of cicada sightings, there have been tens of thousands of reports in Cincinnati and its northern suburbs. But if you head south, crossing the Ohio River into Northern Kentucky, cicada reports dwindle until you hit Louisville and Lexington, per the map.
So when will these cicadas go away?
The 17-year cicadas are only around for a few weeks, according to the Ohio Department of Natural Resources, as they seek mates and lay eggs for the next generation. And while they started to emerge in mid-May, they are still going strong. Kritsky attributed the slow emergence to cooler, rainy days in May. Cicadas need the soil temperatures to hit 64 degrees to emerge, per ODNR, which typically happens in the second half of May.
Following his recent mapping excursion, Kritsky said the big die-off has not yet begun. "The cicadas are still mostly in the trees singing," he said in a June 17 email.
But he expects it to start soon.
"People should notice the loud singing declining over the next two weeks, and the singing should be over in early July," he said previously.
Brood XIV is one of 15 recognized broods of periodical cicadas that emerge every 13 or 17 years, and one of four that appear in the Buckeye State, according to ODNR.
They are active for three to four weeks as they focus on mating and reproduction, per ODNR. Male periodical cicadas produce a deafening chorus of calls to attract females. Once mated, female cicadas deposit their eggs into the branches of trees and shrubs.
Annual cicadas emerge worldwide each year, but periodical cicadas are found only in eastern North America. They live underground as nymphs for either 13 or 17 years before emerging above ground in massive numbers. Different populations of periodical cicadas are called 'broods' and are numbered with Roman numerals.
One of the biggest tourist attractions in Southwest Ohio — Kings Island, in Mason — is also in the center of one of the largest cicada emergences. And some visitors have taken to TikTok to share their disgust, the Enquirer reported on June 11.
Videos show people ducking to get away from the bugs, or just running off in some cases. And their screaming is audible in each one.
Kritsky told Scripps News Services that he has one important piece of advice for Kings Island visitors.
"Just enjoy the cicadas, and when you're on the ride, keep your mouth closed," he said.
Brood XIV cicadas of 2025 will stretch from northern Georgia to Massachusetts. In Ohio, they were expected to emerge in a more than dozen counties, per ODNR, mostly in Southwest Ohio:
Adams
Brown
Butler
Champaign
Clermont
Clinton
Gallia
Greene
Hamilton
Highland
Jackson
Lawrence
Pike
Ross
Scioto
Warren
Washington
Some of the edge counties will not see as heavy an emergence as others.
The cicadas that emerge every 13 or 17 years are different from the ones seen every summer, and it's not just the amount of time.
Kritsky told WKRN in Nashville that periodical cicadas emerge in May or June, while annual cicadas show up later, in late June and July, and through the rest of summer.
The two types also look different from each other. Periodical cicadas have black bodies with red eyes and red-orange wings and can be anywhere from three-quarters of an inch to an inch and one-quarter in length. Annual cicadas have dark green to black bodies with green-veined wings and black eyes and are larger. They can grow to an inch and one-third in length.
Any animal that can eat insects will eat cicadas, according to the Purdue University Extension. Those include fish, bears, birds, raccoons and even other insects, like parasitic wasps.
They're also safe for your dog to eat, to a point.
According to the American Kennel Club, a dog that eats the occasional cicada should be fine. However, dogs that gorge on cicadas will find their exoskeletons difficult to digest, resulting in an upset stomach, abdominal pain, vomiting and bloody diarrhea. Some dogs that overconsume cicadas may require a trip to the vet for IV fluids, or pain and anti-nausea medications.
This article originally appeared on Cincinnati Enquirer: Here's where cicadas are the worst in Cincinnati, Ohio. See the map

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

23 minutes ago

• Medscape

Once-Weekly Efsitora Noninferior to Daily Insulin in T2D

CHICAGO — The investigational once-weekly basal insulin analog efsitora alfa lowered A1c as effectively as daily basal insulins in people with type 2 diabetes (T2D) who require insulin, showed three trials from the QWINT global phase 3 clinical trial program. However, two of the trials showed increased mild hypoglycemia in patients treated with efsitora, which some experts say is a concern. The QWINT-1 trial compared the efficacy and safety of a fixed-dose regimen of efsitora with once-daily glargine for 52 weeks in insulin-naive people with T2D; QWINT-3 compared efsitora with daily degludec for 78 weeks in adults already taking basal insulin; and QWINT-4 compared efsitora with daily glargine for 26 weeks in adults with T2D taking both basal and pre-meal bolus insulin. Results from the three trials were presented on June 22 during a single symposium here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in the New England Journal of Medicine (QWINT-1) and The Lancet (QWINT-3 and QWINT-4). QWINT-1: Fixed-Dose Efsitora QWINT-1 was an open-label trial of 795 adults with T2D who had not previously taken insulin. Participants were randomized to weekly efsitora delivered by a single-use auto-injector or daily injected insulin glargine. Efsitora was titrated to four fixed doses at 4-week intervals, as needed for blood glucose control. At week 52, efsitora had reduced A1c from 8.20% at baseline to 7.05% (–1.19 percentage points), compared with 8.28% to 7.08% with glargine (–1.16 percentage points), confirming noninferiority. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, with titration options of only four different doses, can facilitate and substantially simplify initiating and escalating insulin therapy, potentially changing the insulin management paradigm in type 2 diabetes," lead investigator Julio Rosenstock, MD, senior scientific advisor for Velocity Clinical Research and clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas, said during a press briefing held at the meeting. In addition, the rate of combined clinically significant hypoglycemia (< 54 mg/dL) or severe hypoglycemia (requiring assistance for treatment) was significantly lower with efsitora than glargine (0.50 vs 0.88 events per participant-year of exposure with glargine [estimated rate ratio, 0.57]). In an editorial accompanying QWINT-1, NEJM Deputy Editor Julie R. Ingelfinger, MD, and Clifford J. Rosen, MD, director of clinical and translational research and a senior scientist at Maine Medical Center's Research Institute, Scarborough, write: "The present trial of efsitora potentially offers a ready-made and possibly straightforward algorithm for dose escalation. If packaged at a widely affordable price, efsitora would most likely simplify glycemic control for many persons with type 2 diabetes." However, limitations of QWINT-1 include the open-label design and lack of use of continuous glucose monitoring (CGM), Ingelfinger and Rosen note. QWINT-3 and QWINT-4 In both QWINT-3 and QWINT-4, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. In QWINT-3, 986 adults with T2D who had already been treated with basal insulin and other noninsulin glucose-lowering medications, were randomized 2:1 to weekly efsitora or daily degludec. At week 26, A1c decreased by 0.81 percentage points with efsitora versus 0.72 with degludec, also meeting the noninferiority margin. Combined level 2 and 3 hypoglycemia from baseline to week 78 was similar in the efsitora and degludec groups, at 0.84 versus 0.74 events per patient-year, respectively. However, level 1 (mild) hypoglycemia was significantly more common with efsitora (8.34 vs 6.05; P = .0005). Nine deaths occurred during the trial but none were related to study treatment. In QWINT-4, 730 participants with T2D who had been treated with both basal and prandial insulin and up to three noninsulin glucose-lowering agents were randomized to efsitora or glargine U100, both with premeal insulin lispro. Mean baseline A1c was 8.18%. At 26 weeks, mean A1c was 7.17% in the efsitora group and 7.18% in the glargine group, meeting noninferiority criteria. As in QWINT-3, rates of moderate/severe hypoglycemia in QWINT-4 did not differ between the efsitora and glargine groups (6.6 vs 5.9 events per patient-year; P = .44), but mild hypoglycemia was more common with efsitora (25.3 vs 19.0; P < .0004). Other adverse event rates were similar. Is Hypoglycemia a Problem With Weekly Insulin? These three new studies round out the QWINT program, as results from QWINT-5, in type 1 diabetes (T1D), and from QWINT-2, in insulin-naive adults with T2D, were presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting. Hypoglycemia emerged as a significant issue with efsitora compared with insulin degludec in adults with T1D in the QWINT-5 trial. Another once-weekly insulin analog, Novo-Nordisk's insulin Icodec, has been approved under the brand name Awiqli in the European Union, Canada, Australia, Japan, and Switzerland for T1D and T2D, and in China for T2D. However, the US Food and Drug Administration requested more data to address the concern about hypoglycemia in T1D. "The risk of hypoglycemia remains a crucial factor when evaluating the safety of novel insulin preparations with a long half-life, such as efsitora, which has a half-life of 17 days," wrote Edith WK Chow, MD, and Elaine Chow, MD, PhD, both of The Chinese University of Hong Kong, in an editorial accompanying QWINT-3 and QWINT-4. "In both trials, the efsitora group had higher rates of overall level 1 hypoglycemia. When stratified by study timeline, higher rates of hypoglycemia were observed within the first 12 weeks of the study in both trials," they point out. In addition, they note that because CGM use was only intermittent and masked for participants, "the actual rate of hypoglycemic events might be underestimated, especially in the presence of hypoglycemia unawareness, which has been reported to be as high as 40% of people with type 2 diabetes using continuous glucose monitoring. Even asymptomatic episodes might be associated with increased cardiovascular risk." Asked about this at the press briefing, Rosenstock said that the increased mild hypoglycemia was "just little numerical imbalances. And the most important thing is that the number of events per patient per year are very low. It's less than one event per patient per year. I think that is something that we can take." Asked to comment on all three new QWINT studies, independent industry consultant Charles Alexander, MD, told Medscape Medical News : "Whether once-weekly insulin will be an advantage compared to once-daily insulin will depend upon factors like cost, convenience, and individual preference." Ingelfinger and Rosen agree with Alexander that the use of efsitora may depend on coverage, cost, and availability. "Long-term, formal government approval for efsitora is awaited, and uptake by patients is not yet known," they write. "The advent of newer or more effective noninsulin hypoglycemic drugs such as the GLP-1 receptor agonists, which simultaneously also produce weight loss, might ultimately be a more appealing option than efsitora and allow greater patient adherence than weekly insulin in some patients with type 2 diabetes." Despite these unknowns and caveats, the development of even longer-acting insulins now offers promising options for better glucose control in this disease," Ingelfinger and Rosen conclude. Rosenstock has reported receiving research grant support from, serving on advisory boards for, and/or receiving consulting fees honoraria from Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Regeneron, Regor Therapeutics, Roche, Sanofi, Structure Therapeutics, and Terns Pharmaceuticals. Ingelfinger is a licensee of St. Martin's Press. Edith WK Chow has reported receiving travel sponsorship from Boehringer Ingelheim. Elaine Chow has reported receiving speaker honoraria from AstraZeneca, Boehringer Ingelheim, and Sinocare and institutional research grant support from Hua Medicine, Merck KGaA, and Medtronic Diabetes. All proceeds were donated to The Chinese University of Hong Kong for research purposes. Rosen and Alexander had no disclosures.

Yahoo

an hour ago

• Yahoo

New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing

Data Presented at the 2025 American Society for Microbiology Microbe Conference BOSTON, June 22, 2025--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. "This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup," said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. "This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections." The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? "These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical," said Brad Murray, chief executive officer of Delve Bio. "We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need." Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on Contacts Company Contact Amy WongSenior Director of Marketing and Business Development, Delve BioEmail: media@ Media Contact Julie McKeough42 North for Delve BioEmail: julie@ Sign in to access your portfolio

Washington Post

2 hours ago

• Washington Post

A Jeep drove onto the National Mall, weaving around a summer crowd

Ferdous Al-Faruque and his date were running late. It was their second date. They had tickets to Sally's Night — an annual event honoring Sally Ride, the first American woman in space — on Saturday at the National Air and Space Museum and had just finished getting drinks at Penn Quarter Sports Tavern on the opposite side of the National Mall.